Also known as: JAK2
AI-driven studies are advancing cancer drug discovery across multiple tumor types, including a pan-cancer proposal of AMG-900, a novel gp130 inhibitor for colorectal cancer, and the Kinic Index for hepatocellular carcinoma. Machine learning is also being integrated into computational platforms like Isomorphic Labs' IsoDDE to model molecular interactions.
Ruxolitinib remains the standard frontline therapy for intermediate-2 and high-risk myelofibrosis, with phase 3 and real-world data showing spleen and symptom benefits. Cytopenias, transfusion needs and resistance after 2 to 3 years continue to drive interest in new combinations.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
